EPRX 株価分析 — Eupraxia Pharmaceuticals Inc. Common Stock (Healthcare >> Biotechnology)
EPRX に関するよくある質問
EPRXのROE(自己資本利益率)は?
Eupraxia Pharmaceuticals Inc. Common StockのROEは-30.84%です。
EPRXの配当利回りは?
Eupraxia Pharmaceuticals Inc. Common Stockの配当利回りは0.00%です。
EPRXの品質スコア(Quality Score)は?
当社のAIはEPRXの総合財務品質を100点中46点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
EPRXは今が買い時ですか?
当社AIのタイミングスコアは100点中50点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
EPRXはどのセクターに属しますか?
Eupraxia Pharmaceuticals Inc. Common StockはHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
EPRX AI Analysis Summary
Our AI summary for EPRX: Eupraxia Pharmaceuticals Inc. Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -30.84%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 50/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 6.52
Price
0.01
(0.15%)
Day Change
|
|
|---|
EPRX, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 6.52 |
| PBV / Sector |
3.12 / 44,022.72
|
| Earning Per Share | -0.65 |
| PE / Sector |
N/A / 19.17
|
| PEG or PE/Growth / Sector |
N/A / 1.24
|
| Average 1M Daily Value |
2.27 M
GREAT
|
| Average 1W Daily Value |
3.41 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
39% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-08-05 08:00:09 |
| Symbol | EPRX |
| Name | EUPRAXIA PHARMACEUTICALS INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 65.33 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 425.28 / 9,586.08 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2067 Cadboro Bay Road, Victoria, BC, Canada, V8R 5G4
Phone: 250 590 3968
Website: https://www.eupraxiapharma.com
Sector: Healthcare >> Biotechnology
Description: Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google